Madrigal Pharmaceuticals, Inc. (MDGL)
467.85
-3.90
(-0.83%)
USD |
NASDAQ |
Oct 12, 11:15
Madrigal Pharmaceuticals Free Cash Flow (Quarterly) : 19.08M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 19.08M |
| March 31, 2026 | -171.28M |
| December 31, 2025 | -133.07M |
| September 30, 2025 | 75.99M |
| June 30, 2025 | -47.05M |
| March 31, 2025 | -88.89M |
| December 31, 2024 | -104.68M |
| September 30, 2024 | -67.76M |
| June 30, 2024 | -140.08M |
| March 31, 2024 | -149.51M |
| December 31, 2023 | -80.97M |
| September 30, 2023 | -85.26M |
| June 30, 2023 | -75.38M |
| March 31, 2023 | -84.10M |
| December 31, 2022 | -58.54M |
| September 30, 2022 | -59.10M |
| June 30, 2022 | -57.46M |
| March 31, 2022 | -49.96M |
| December 31, 2021 | -48.16M |
| September 30, 2021 | -45.61M |
| June 30, 2021 | -46.88M |
| March 31, 2021 | -43.47M |
| December 31, 2020 | -54.96M |
| September 30, 2020 | -47.85M |
| June 30, 2020 | -24.26M |
| Date | Value |
|---|---|
| March 31, 2020 | -30.82M |
| December 31, 2019 | -12.42M |
| September 30, 2019 | -11.32M |
| June 30, 2019 | -11.54M |
| March 31, 2019 | -6.519M |
| December 31, 2018 | -6.273M |
| September 30, 2018 | -5.251M |
| June 30, 2018 | -5.36M |
| March 31, 2018 | -8.645M |
| December 31, 2017 | -5.945M |
| September 30, 2017 | -4.951M |
| June 30, 2017 | -7.773M |
| March 31, 2017 | -3.773M |
| December 31, 2016 | -5.282M |
| September 30, 2016 | -9.244M |
| June 30, 2016 | -2.647M |
| March 31, 2016 | -0.438M |
| December 31, 2015 | -1.096M |
| September 30, 2015 | 34.49M |
| June 30, 2015 | -17.76M |
| March 31, 2015 | -18.78M |
| December 31, 2014 | -19.27M |
| September 30, 2014 | -18.60M |
| June 30, 2014 | -20.90M |
| March 31, 2014 | -20.29M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 292.04M |
| Insmed, Inc. | -95.09M |
| United Therapeutics Corp. | 202.20M |
| Karyopharm Therapeutics, Inc. | -24.93M |
| ACADIA Pharmaceuticals, Inc. | 95.69M |